P14. Elderly patients with NSCLC with brain mets-need for combined targeted therapy

Abstract

Background Non-small cell lung cancer (NSCLC) with brain metastases is usually associated with poor outcomes and survival and about 40-50% of all patients with lung cancer develop brain metastases during the course. The poor outcomes and relapses following WBRT alone indicate a need for new therapeutic options. As some patients with NSCLC have mutations in the epidermal growth factor receptor (EGFR) and treating with WBRT with the anti-EGFR agent erlotinib in patients of NSCLC with brain metastases may benefit the patients in terms of disease regression and possible improvement in quality of life. Temozolomide has been already used alone or in combination with radiotherapy in the treatment of primary brain tumors and there are few studies showing its benefits in metastatic brain with WBRT. In this study we test the feasibility and efficacy of both of the drugs with WBRT.